Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First-in-Human Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Phase 1 Study.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1600
Abstract: Bexicaserin (LP352) is a selective 5-hydroxytryptamine 2C (5-HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double-blind, placebo-controlled, single ascending dose (SAD) Phase 1 study aimed to assess… read more here.
Keywords: bexicaserin; safety tolerability; placebo; study ... See more keywords
Diazepine Agonists of the 5‑HT2C Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.4c02923
Abstract: The clinical development of novel 5-HT2C receptor (5-HT2CR) therapies has been limited due to concerns over lack of selectivity and potential for off-target effects. Here, we report that the introduction of a secondary amide substituent… read more here.
Keywords: unprecedented selectivity; diazepine agonists; bexicaserin; selectivity ... See more keywords